

| Catalog No. | DY286018 |
|---|---|
| Sample type | Plasma, Serum |
| Sensitivity | 0.156 μg/ml |
| Range | 0.31-5 μg/mL |
| Accession | P04626 |
| Applications | ELISA |
| Detection method | Colorimetric |
| Assay type | Quantitative |
| Recovery | 80-120% |
| Shipping | 2-8 ℃ |
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Specifications | Disitamab |
| Alternate Names | RC48-0, Disitamab Vedotin, 2185868-98-6 |
| Background | Receptor tyrosine-protein kinase erbB-2 (Disitamab) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. |
| References | 1. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935. [DY286018] 2. Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. [DY286018] 3. Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61. [DY286018] |
| Note | For Research Use Only. |




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com
+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский